Ivabradin Krka
Selective Heart Rate-Lowering Agent for Angina and Heart Failure
Quick Facts About Ivabradin Krka
Key Takeaways
- Ivabradin Krka selectively lowers heart rate without affecting blood pressure, contractility, or cardiac conduction, making it unique among cardiovascular medications.
- It is indicated for stable angina pectoris (heart rate ≥70 bpm) and chronic heart failure (heart rate ≥75 bpm) in adults, often used when beta-blockers are insufficient or not tolerated.
- The most distinctive side effect is visual luminous phenomena (phosphenes), which are generally mild, transient, and tend to resolve during continued treatment.
- Ivabradine is contraindicated during pregnancy and breastfeeding, and women of childbearing potential must use reliable contraception throughout treatment.
- Strong CYP3A4 inhibitors (ketoconazole, HIV protease inhibitors, macrolide antibiotics) and the calcium channel blockers verapamil and diltiazem must not be used concurrently with ivabradine.
What Is Ivabradin Krka and What Is It Used For?
Ivabradin Krka belongs to a unique pharmacological class known as selective If channel inhibitors. The active ingredient, ivabradine, targets the funny current (If) in the sinoatrial node of the heart – the natural pacemaker that controls heart rhythm. By selectively blocking this ion channel, ivabradine reduces the rate of spontaneous diastolic depolarisation in pacemaker cells, resulting in a dose-dependent reduction in heart rate.
What makes ivabradine distinct from other heart rate-lowering medications, particularly beta-blockers, is its remarkable selectivity. Unlike beta-blockers, which also reduce cardiac contractility (the force with which the heart pumps) and lower blood pressure, ivabradine exclusively targets heart rate. This means the heart pumps at a slower rate but with undiminished force, and blood pressure remains essentially unchanged. This pharmacological profile is particularly advantageous in patients who experience side effects from beta-blockers such as fatigue, cold extremities, or excessive blood pressure reduction.
Stable Angina Pectoris
Stable angina pectoris, commonly referred to as angina or chest pain on exertion, occurs when the heart muscle does not receive sufficient oxygen-rich blood, typically due to narrowing of the coronary arteries from atherosclerosis. The most common symptom is a feeling of pressure, tightness, or pain in the chest, which typically occurs during physical activity or emotional stress and subsides with rest.
By lowering heart rate, ivabradine reduces the heart’s oxygen demand. A slower heart rate means the heart has more time to fill with blood during diastole (the relaxation phase), which improves coronary perfusion – the blood supply to the heart muscle itself. The European Society of Cardiology (ESC) 2024 guidelines on chronic coronary syndromes recognise ivabradine as an effective second-line anti-anginal therapy, particularly in patients with sinus rhythm who are intolerant of or inadequately controlled by beta-blockers.
For stable angina, Ivabradin Krka is prescribed to adults whose resting heart rate is 70 beats per minute or above. It may be used alone when beta-blockers are contraindicated or not tolerated, or in combination with a beta-blocker when the patient’s condition is not adequately controlled by beta-blocker monotherapy.
Chronic Heart Failure
Chronic heart failure is a progressive condition in which the heart cannot pump blood efficiently enough to meet the body’s needs. Common symptoms include breathlessness (dyspnoea), fatigue, reduced exercise capacity, and fluid retention causing swollen ankles and legs. Heart failure affects approximately 1–2% of the adult population in developed countries, with prevalence increasing sharply with age.
In patients with chronic heart failure and reduced ejection fraction (HFrEF), an elevated resting heart rate is associated with worse outcomes. The landmark SHIFT trial (Systolic Heart failure treatment with the If inhibitor ivabradine Trial), published in The Lancet in 2010, demonstrated that adding ivabradine to standard heart failure therapy significantly reduced the composite endpoint of cardiovascular death and heart failure hospitalisation by 18%. The ESC 2023 heart failure guidelines recommend ivabradine for symptomatic patients with a left ventricular ejection fraction ≤35%, in sinus rhythm, and with a resting heart rate ≥70 bpm despite maximum tolerated beta-blocker dose.
For chronic heart failure, Ivabradin Krka is prescribed to adults whose resting heart rate is 75 beats per minute or above. It is used in combination with standard treatment including beta-blockers, or when beta-blockers are contraindicated or cannot be tolerated.
How Does Ivabradine Work?
The specific heart rate-lowering effect of ivabradine works through two key mechanisms related to the heart’s oxygen balance:
- Controls and reduces angina attacks by lowering the heart’s oxygen demand – a slower heart rate means less energy expenditure, which reduces the likelihood of oxygen supply–demand mismatch that triggers chest pain.
- Improves cardiac function and prognosis in chronic heart failure by allowing more time for ventricular filling during diastole, improving stroke volume, and reducing the neurohumoral activation that drives disease progression.
What Should You Know Before Taking Ivabradin Krka?
Contraindications
There are several important situations where Ivabradin Krka must not be used. These absolute contraindications exist because the drug could cause serious or life-threatening harm in these circumstances:
- You are allergic to ivabradine or any of the other ingredients
- Your resting heart rate before treatment is below 70 beats per minute
- You have cardiogenic shock (a critical heart condition treated in hospital)
- You have heart rhythm disorders including sick sinus syndrome, sinoatrial block, or third-degree atrioventricular block
- You are experiencing an acute myocardial infarction (heart attack)
- You have very low blood pressure (severe hypotension – systolic below 90 mmHg or diastolic below 50 mmHg)
- You have unstable angina (a serious condition where chest pain occurs frequently and unpredictably)
- You have heart failure that has recently worsened acutely
- Your heart rhythm is entirely maintained by a pacemaker
- You have severe liver impairment
- You are using strong CYP3A4 inhibitors such as ketoconazole, itraconazole, josamycin, clarithromycin, telithromycin, oral erythromycin, nelfinavir, ritonavir, nefazodone, diltiazem, or verapamil
- You are a woman of childbearing potential not using reliable contraception
- You are pregnant, trying to become pregnant, or breastfeeding
Warnings and Precautions
Before starting treatment with Ivabradin Krka, it is essential to discuss your full medical history with your prescribing physician. Several conditions require special caution or close monitoring during ivabradine therapy:
- Heart rhythm disorders: If you have any cardiac arrhythmia, palpitations, or a history of increased chest pain, your doctor needs to carefully assess the benefit–risk balance. Patients with sustained atrial fibrillation should not initiate ivabradine.
- Symptoms of excessive heart rate reduction: Fatigue, dizziness, or breathlessness may indicate that your heart rate has been lowered too much. Your doctor may need to reduce the dose or discontinue treatment.
- Atrial fibrillation: If you notice an unusually fast resting heart rate (above 110 bpm) or irregular pulse, contact your doctor. Ivabradine increases the risk of atrial fibrillation, which occurs in approximately 5% of patients.
- Recent stroke: Extra caution is warranted in patients who have recently had a cerebrovascular event.
- Low blood pressure: If you have mild to moderate hypotension, or if your blood pressure is not fully controlled (especially after changing antihypertensive treatment), close monitoring is needed.
- Severe heart failure or bundle branch block: If you have NYHA class IV heart failure or ECG abnormalities known as bundle branch block, careful clinical assessment is required.
- Chronic retinal conditions: If you have retinitis pigmentosa or other chronic retinal diseases, your ophthalmologist should be consulted, as ivabradine can cause visual disturbances.
- Liver or kidney impairment: Moderate hepatic impairment requires dose adjustment; severe hepatic impairment is a contraindication. Severe renal impairment (creatinine clearance below 15 mL/min) requires caution due to limited clinical data.
Pregnancy and Breastfeeding
Ivabradine is strictly contraindicated during pregnancy. Animal reproductive studies have shown teratogenic effects (birth defects) and embryotoxicity. Women of childbearing potential must use effective contraception throughout treatment. If you discover you are pregnant while taking Ivabradin Krka, stop the medication immediately and consult your doctor urgently.
Breastfeeding is also contraindicated during ivabradine treatment. Studies have demonstrated that ivabradine passes into breast milk in animal models. If treatment with ivabradine is necessary, breastfeeding should be discontinued to avoid potential adverse effects on the infant.
If you are planning to become pregnant, discuss alternative treatment options with your cardiologist well in advance so that an appropriate transition to a pregnancy-safe medication can be arranged.
How Does Ivabradin Krka Interact with Other Drugs?
Understanding drug interactions with Ivabradin Krka is critical for safe and effective treatment. Because ivabradine is extensively metabolised by the cytochrome P450 3A4 (CYP3A4) enzyme system in the liver and intestine, any medication that significantly affects CYP3A4 activity can alter ivabradine blood levels. Additionally, medications that affect heart rate or cardiac conduction may have additive effects when combined with ivabradine.
Major Interactions (Contraindicated Combinations)
The following medications must never be taken concurrently with Ivabradin Krka, as the combination can lead to dangerous increases in ivabradine blood levels or additive cardiac effects:
| Drug / Class | Examples | Reason |
|---|---|---|
| Azole antifungals | Ketoconazole, itraconazole | Strong CYP3A4 inhibitors – can increase ivabradine levels 7–8 fold |
| Macrolide antibiotics | Josamycin, clarithromycin, telithromycin, oral erythromycin | Strong CYP3A4 inhibitors – significantly elevate ivabradine plasma concentration |
| HIV protease inhibitors | Nelfinavir, ritonavir | Strong CYP3A4 inhibitors – dangerous increase in drug exposure |
| Non-dihydropyridine calcium channel blockers | Verapamil, diltiazem | CYP3A4 inhibition plus additive heart rate-lowering effect |
| Antidepressants | Nefazodone | Strong CYP3A4 inhibitor – markedly increases ivabradine levels |
Interactions Requiring Caution
Several other medications interact with ivabradine at a level that does not absolutely prohibit concurrent use but requires careful clinical monitoring, possible dose adjustments, or awareness of increased risk:
| Drug / Class | Examples | Clinical Consideration |
|---|---|---|
| Moderate CYP3A4 inhibitors | Fluconazole | Starting dose of 2.5 mg twice daily recommended; monitor heart rate |
| CYP3A4 inducers | Rifampicin, barbiturates, phenytoin, St John’s Wort | May reduce ivabradine efficacy; dose increase may be required |
| QT-prolonging antiarrhythmics | Quinidine, disopyramide, ibutilide, sotalol, amiodarone | Additive risk of cardiac rhythm disturbances; careful ECG monitoring needed |
| Other QT-prolonging drugs | Pimozide, ziprasidone, sertindole, mefloquine, halofantrine, pentamidine, cisapride | Additive QT prolongation risk; avoid if possible or monitor closely |
| Potassium-depleting diuretics | Furosemide, hydrochlorothiazide, indapamide | Low potassium increases arrhythmia risk; monitor electrolytes |
Food and Drink Interactions
Grapefruit juice must be avoided during treatment with Ivabradin Krka. Grapefruit contains compounds (furanocoumarins) that inhibit intestinal CYP3A4 enzymes, which can approximately double ivabradine blood levels. This can lead to excessive heart rate reduction and increased risk of side effects including pronounced visual disturbances, dizziness, and symptomatic bradycardia.
Ivabradin Krka should always be taken with meals, as food increases the absorption of the active substance by approximately 20–30%, leading to more consistent drug levels.
Driving and Operating Machinery
Ivabradine can cause transient luminous visual phenomena (phosphenes), particularly during sudden changes in light intensity. If you experience these visual effects, exercise caution when driving, especially at night or when passing through tunnels. You should assess your own fitness to drive. Dizziness, which is a common side effect, may also impair your ability to operate machinery safely.
What Is the Correct Dosage of Ivabradin Krka?
Always take Ivabradin Krka exactly as prescribed by your doctor. The tablets should be taken twice daily – once in the morning and once in the evening – with meals to optimise absorption. The 5 mg film-coated tablet has a score line and can be divided into two equal halves for flexible dosing. Do not crush or chew the tablets.
Adults – Stable Angina Pectoris
Starting Dose
5 mg twice daily (one 5 mg tablet in the morning and one in the evening). In some cases, particularly in patients aged 75 years or older, your doctor may prescribe a lower starting dose of 2.5 mg twice daily (half a 5 mg tablet morning and evening).
Dose Adjustment
After 3–4 weeks of treatment, if symptoms persist and the 5 mg dose has been well tolerated, the dose may be increased to 7.5 mg twice daily. The maximum recommended dose is 7.5 mg twice daily.
Adults – Chronic Heart Failure
Starting Dose
5 mg twice daily. For patients aged 75 years or older, a starting dose of 2.5 mg twice daily (half a 5 mg tablet) may be considered.
Dose Titration
After two weeks, the dose may be increased to 7.5 mg twice daily if the resting heart rate remains persistently above 60 bpm, or decreased to 2.5 mg twice daily if the resting heart rate is persistently below 50 bpm or the patient experiences bradycardia-related symptoms.
| Indication | Starting Dose | Maintenance Dose | Maximum Dose |
|---|---|---|---|
| Stable angina (adults) | 5 mg twice daily | 5–7.5 mg twice daily | 7.5 mg twice daily |
| Chronic heart failure (adults) | 5 mg twice daily | 5–7.5 mg twice daily | 7.5 mg twice daily |
| Elderly (≥75 years) | 2.5 mg twice daily | 2.5–7.5 mg twice daily | 7.5 mg twice daily |
Children and Adolescents
Ivabradin Krka is not approved for use in children or adolescents under 18 years of age. Sufficient data on safety and efficacy in this population are not available. Do not give this medicine to a child.
Missed Dose
If you forget to take a dose of Ivabradin Krka, simply take the next dose at your regular scheduled time. Do not take a double dose to compensate for the one you missed. Missing an occasional dose is unlikely to cause significant problems, but regular adherence to the twice-daily schedule is important for consistent heart rate control.
Overdose
Stopping Treatment
Treatment for angina pectoris or chronic heart failure is typically long-term. Do not stop taking Ivabradin Krka without consulting your doctor, even if you feel well. Abrupt discontinuation does not cause a withdrawal syndrome (unlike some beta-blockers), but your underlying condition may worsen without continued treatment. If you feel the medication is too strong or too weak, speak with your doctor rather than adjusting the dose yourself.
What Are the Side Effects of Ivabradin Krka?
Like all medicines, Ivabradin Krka can cause side effects, although not everybody gets them. The most frequent side effects are directly related to ivabradine’s mechanism of action – its effect on heart rate and on retinal If channels (which are structurally similar to the cardiac If channels). The majority of side effects are dose-dependent and can often be managed by dose reduction rather than treatment discontinuation.
Very Common
Affects more than 1 in 10 people
- Luminous phenomena (phosphenes) – brief episodes of enhanced visual brightness, often described as a halo of light, coloured flashes, image decomposition, or multiple images. Typically triggered by sudden changes in light intensity. Most common in the first two months of treatment and generally mild and transient.
Common
Affects up to 1 in 10 people
- Bradycardia – abnormally slow heart rate, typically within the first 2–3 months of treatment
- Atrial fibrillation – irregular, often rapid heart rhythm
- Abnormal perception of heartbeats – first-degree AV block (prolonged PR interval on ECG), ventricular extrasystoles
- Uncontrolled blood pressure
- Headache
- Dizziness
- Blurred vision
Uncommon
Affects up to 1 in 100 people
- Palpitations and extra heartbeats
- Nausea, constipation, diarrhoea, abdominal pain
- Vertigo (spinning sensation)
- Dyspnoea (shortness of breath)
- Muscle spasms
- Elevated uric acid, increased eosinophils, elevated creatinine
- Skin rash, angioedema (swelling of face, tongue, or throat)
- Hypotension (low blood pressure), syncope (fainting)
- Fatigue, asthenia (weakness)
- Abnormal ECG pattern
- Diplopia (double vision), visual impairment
Rare
Affects up to 1 in 1,000 people
- Urticaria (hives), pruritus (itching), erythema (skin redness)
- Malaise (general feeling of unwellness)
Very Rare
Affects up to 1 in 10,000 people
- Second-degree AV block
- Third-degree AV block
- Sick sinus syndrome
Understanding Luminous Phenomena
The most distinctive side effect of ivabradine is luminous visual phenomena, medically known as phosphenes. These occur because the If channels in retinal ganglion cells are structurally similar to those in the heart, and ivabradine can partially inhibit these retinal channels. Patients typically describe seeing brief flashes of brighter light, a glowing ring around light sources, or temporary image fragmentation – most often when transitioning between different lighting conditions (e.g., entering a dark room from bright sunlight, or passing through a tunnel while driving).
These visual effects are reported by approximately 14.5% of patients. They are generally mild, occur most frequently during the first two months of treatment, and tend to diminish over time with continued use. In clinical trials, only about 1% of patients discontinued treatment due to phosphenes. However, if visual disturbances significantly impact your daily life, consult your doctor about dose adjustment.
How Should You Store Ivabradin Krka?
Proper storage of medications is essential to maintain their efficacy and safety. Ivabradin Krka does not require any special storage conditions – it can be kept at normal room temperature. However, as with all medications, there are important general guidelines to follow:
- Keep out of the sight and reach of children. Store in a secure location that children cannot access.
- Check the expiry date on the carton and blister pack before each use. The expiry date refers to the last day of the stated month. Do not use the medicine after this date.
- Store in the original packaging to protect the tablets from moisture and light exposure.
- Do not dispose of medicines via wastewater or household waste. Return unused or expired medicines to your pharmacist for proper disposal. These measures help protect the environment from pharmaceutical contamination.
What Does Ivabradin Krka Contain?
Active Substance
The active pharmaceutical ingredient is ivabradine, present as ivabradine hydrochloride. The 5 mg tablet contains 5 mg of ivabradine (equivalent to approximately 5.39 mg of ivabradine hydrochloride), and the 7.5 mg tablet contains 7.5 mg of ivabradine (equivalent to approximately 8.085 mg of ivabradine hydrochloride).
Inactive Ingredients (Excipients)
Tablet core: Maltodextrin, lactose monohydrate, maize starch, colloidal anhydrous silica, magnesium stearate (E470b), hypromellose 3 cP.
Film coating: Hypromellose 6 cP, titanium dioxide (E171), talc, propylene glycol, yellow iron oxide (E172), red iron oxide (E172).
Tablet Appearance and Packaging
5 mg tablets: Light pinkish-orange, rectangular, slightly biconvex film-coated tablets with a score line on one side, measuring 8 mm × 4.5 mm. The tablet can be divided into two equal halves.
7.5 mg tablets: Light pinkish-orange, round, slightly biconvex film-coated tablets with bevelled edges, 7 mm in diameter.
Ivabradin Krka is available in cartons containing 14, 28, 56, 98, 112, and 180 film-coated tablets in blister packs, as well as perforated unit-dose blisters of 14 × 1, 28 × 1, 56 × 1, 98 × 1, 112 × 1, and 180 × 1 tablets. Not all pack sizes may be marketed in all countries.
Manufacturer
Ivabradin Krka is manufactured by KRKA, d.d., Novo mesto, based in Slovenia. KRKA is a major European pharmaceutical company specialising in generic medicines and has been producing high-quality pharmaceutical products since 1954.
Frequently Asked Questions About Ivabradin Krka
Both ivabradine and beta-blockers lower heart rate, but they work through completely different mechanisms. Beta-blockers (such as bisoprolol, metoprolol, or carvedilol) block adrenaline receptors throughout the body, which reduces heart rate, blood pressure, and cardiac contractility. This means they also cause side effects like fatigue, cold extremities, and bronchospasm. Ivabradine exclusively targets the If channel in the sinus node, lowering heart rate without affecting blood pressure, contractility, or bronchial tone. This makes it better suited for patients who cannot tolerate beta-blockers. In clinical practice, ivabradine and beta-blockers are often used together for synergistic heart rate control.
Yes, ivabradine can be safely combined with beta-blockers, and this is in fact a common and recommended approach. For stable angina, ivabradine may be added when a beta-blocker alone does not adequately control heart rate or symptoms. For chronic heart failure, the ESC guidelines specifically recommend ivabradine as an add-on to the maximum tolerated dose of beta-blocker. However, combining ivabradine with the non-dihydropyridine calcium channel blockers verapamil or diltiazem is contraindicated due to excessive heart rate reduction. Your doctor will monitor your heart rate carefully and adjust doses as needed.
Luminous phenomena (phosphenes) are not harmful to the eyes and do not cause any structural damage to the retina or other parts of the visual system. They occur because ivabradine partially inhibits If channels in retinal ganglion cells, which are structurally similar to the cardiac If channels. The visual effects are typically mild, last only seconds, and are most noticeable during sudden changes in lighting. In clinical studies, phosphenes led to treatment discontinuation in only about 1% of patients. However, patients with retinitis pigmentosa or other chronic retinal conditions should consult their ophthalmologist before starting ivabradine.
Ivabradine begins to reduce heart rate within hours of the first dose. Peak plasma concentrations are reached approximately 1 hour after oral administration, and you may notice a reduction in heart rate within the first day. However, the full therapeutic benefit – particularly in terms of angina symptom reduction or heart failure improvement – typically develops over 3–4 weeks of regular treatment. This is why your doctor will usually assess your response and consider dose adjustment after this initial period. Do not increase the dose on your own if you don’t notice immediate effects.
Taking ivabradine with food is important because meals increase the absorption of the active substance by approximately 20–30%. More importantly, food slows down absorption, leading to more predictable and stable drug levels throughout the day. Taking the tablets on an empty stomach can result in more rapid absorption with higher peak levels and greater variability in drug exposure, which may increase the risk of side effects (particularly phosphenes and bradycardia). By taking your morning dose with breakfast and your evening dose with dinner, you ensure the most consistent and effective treatment.
Ivabradin Krka, Procoralan, and Corlentor all contain the same active ingredient – ivabradine – and are available in the same strengths (5 mg and 7.5 mg). Procoralan and Corlentor are the original brand-name products manufactured by Servier, while Ivabradin Krka is a generic version manufactured by KRKA. Generic medicines must meet the same strict regulatory standards for quality, safety, and efficacy as the original brand. Bioequivalence studies have confirmed that Ivabradin Krka produces comparable blood levels and clinical effects to the originator products.
References
This article is based on the following peer-reviewed sources, international clinical guidelines, and regulatory documents. All medical claims reflect evidence level 1A where applicable (systematic reviews and meta-analyses of randomised controlled trials).
- European Medicines Agency (EMA). Procoralan (ivabradine) – Summary of Product Characteristics. Available at: EMA – Procoralan EPAR.
- Swedberg K, Komajda M, Böhm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. The Lancet. 2010;376(9744):875–885. doi: 10.1016/S0140-6736(10)61198-1.
- Fox K, Ford I, Steg PG, et al. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. The Lancet. 2008;372(9641):807–816. doi: 10.1016/S0140-6736(08)61170-8.
- McDonagh TA, Metra M, Adamo M, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal. 2023;44(37):3627–3639. doi: 10.1093/eurheartj/ehad195.
- Vrints C, Andreotti F, Koskinas KC, et al. 2024 ESC Guidelines for the management of chronic coronary syndromes. European Heart Journal. 2024;45(36):3415–3537. doi: 10.1093/eurheartj/ehae177.
- Fox K, Ford I, Steg PG, et al. Ivabradine in stable coronary artery disease without clinical heart failure. New England Journal of Medicine. 2014;371(12):1091–1099. doi: 10.1056/NEJMoa1406430.
- National Institute for Health and Care Excellence (NICE). Ivabradine for treating chronic heart failure. Technology appraisal guidance [TA267]. Available at: NICE TA267.
- British National Formulary (BNF). Ivabradine – Drug Monograph. Available at: BNF – Ivabradine.
- World Health Organization (WHO). Model List of Essential Medicines – 23rd List, 2023. Geneva: WHO; 2023.
About the Medical Editorial Team
This article was written and reviewed by the iMedic Medical Editorial Team, consisting of licensed specialist physicians in cardiology, clinical pharmacology, and internal medicine. Our editorial process follows the GRADE evidence framework, and all content is reviewed against current international clinical guidelines.
All information is based on peer-reviewed research, European Medicines Agency (EMA) regulatory documents, and international guidelines from the ESC, AHA, NICE, and WHO. We adhere to Evidence Level 1A where available – the highest quality of evidence based on systematic reviews of randomised controlled trials.
iMedic receives no commercial funding and has no financial relationships with pharmaceutical companies. All content is editorially independent. Our physicians have no conflicts of interest related to the medications discussed. This independence is fundamental to providing trustworthy medical information.
Our editorial process includes: primary drafting by a specialist physician, independent medical review by a second specialist, fact-checking against primary sources, accessibility review for WCAG 2.2 AAA compliance, and scheduled reviews every 6 months or when significant new evidence emerges.